• Celularity named Rick Gonzalez chief commercial officer, effective May 29, 2026.
• He will run global commercial strategy for cenplacel-L, Lifebank, and the broader regenerative medicine portfolio, reporting to CEO Robert J. Hariri.
• Gonzalez previously served as chief commercial officer at Alume Biosciences, leading commercialization strategy for a clinical-stage surgical visualization platform.
• He was also CEO of Navidea Biopharmaceuticals, driving 2.5x year-over-year revenue growth, and held senior roles at Spectrum Pharmaceuticals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celularity Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606030800PRIMZONEFULLFEED9731118) on June 03, 2026, and is solely responsible for the information contained therein.